ModerateSNRI×Biguanides. Oral antihyperglycemic agents
Updated · Methodology
Mechanism
Metformin is not metabolised: the kidneys excrete it unchanged, and it hardly binds to plasma proteins (Dianben SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In the liver, CYP1A2 and CYP2D6 metabolise duloxetine (duloxetine SmPC, European Medicines Agency, EMA). The duloxetine documents say nothing about the organic cation transporters OCT1 and OCT2 that handle metformin, so no pharmacokinetic pathway links the two drugs. The interaction concerns blood glucose: drugs with an intrinsic hyperglycaemic effect can weaken glycaemic control in people taking metformin (Dianben SmPC, AEMPS; metformin prescribing information, US Food and Drug Administration, FDA). In diabetic neuropathy trials, duloxetine slightly raised fasting blood glucose. In the extension phase of up to 52 weeks, glycated haemoglobin (HbA1c) rose by 0.5% versus 0.2% with routine care, and glycaemic control worsened in some people with diabetes (duloxetine prescribing information, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Worsening glycaemic control shows as a rise in fasting blood glucose and glycated haemoglobin (HbA1c) (duloxetine prescribing information, US Food and Drug Administration, FDA). Metformin most often causes nausea, vomiting, diarrhoea, abdominal pain and loss of appetite, and very rarely lactic acidosis with breathlessness, abdominal pain, muscle cramps and weakness (Dianben SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Duloxetine can raise blood pressure, lower blood sodium and cause dizziness on standing (duloxetine SmPC, European Medicines Agency, EMA).
Management
The combination is not contraindicated, and duloxetine is also used for diabetic peripheral neuropathic pain (duloxetine SmPC, European Medicines Agency, EMA). With drugs that raise blood glucose themselves, check glucose more often, especially at the start. Adjust the metformin dose if needed during treatment with the other drug and after it is stopped (Dianben SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). After such a drug is withdrawn, watch for hypoglycaemia (metformin prescribing information, US Food and Drug Administration, FDA). Duloxetine is not among the examples of this class, but according to its US prescribing information it worsened glycaemic control in some people with diabetes (duloxetine prescribing information, FDA). Assess renal function by glomerular filtration rate (GFR) before starting metformin and regularly after that. Metformin is contraindicated with GFR below 30 mL/min (Dianben SmPC, AEMPS). Do not use duloxetine with creatinine clearance below 30 mL/min (duloxetine SmPC, EMA). Use duloxetine with caution in conditions that may slow gastric emptying, as in some people with diabetes (duloxetine prescribing information, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica Dianben 850 mg comprimidos recubiertos con película (metformina) (2025)– AEMPS, CIMA, nº registro 55211, revisión 03/2025, secciones 4.4 y 4.5
- FDA: Metformin hydrochloride tablets (metformin) prescribing information (2026)– FDA, DailyMed, setid c82a10fa-1e8e-46b6-890a-737de3f34ee1 (Zydus), SPL 07/2026, sections 5.1, 7 and 12.3
- EMA: Ficha técnica: Duloxetina, Cymbalta (EU/1/04/296), sección 4.4 (2024)– EMA, ficha técnica Cymbalta, EU/1/04/296 (CIMA nregistro 04296001), texto publicado por la EMA, PDF de 05/2024, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Duloxetine delayed-release capsules (duloxetine) prescribing information (2026)– FDA, DailyMed, Lupin Pharmaceuticals, setid 829a4f51-c882-4b64-81f3-abfb03a52ebe, revised 05/2026, sections 4, 5.2, 5.4, 5.5, 7.1–7.17 and 12.2